Submitted:
07 August 2024
Posted:
08 August 2024
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Methods
3. Results
4. Discussion
4.1. Grover Disease (GD) – from Clinical to Molecular Understanding
4.2. The Intriguing Puzzle of Grover’s Disease Pathophysiology
4.3. Grover Disease (GD) Association with Cutaneous Keratinocyte Carcinomas
5. Conclusions
Author Contributions
Funding
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Grover RW. Transient Acantholytic Dermatosis. Arch Dermatol 1970;101:426–34. [CrossRef]
- Fernández-Figueras MT, Puig L, Cannata P, et al. Grover disease: a reappraisal of histopathological diagnostic criteria in 120 cases. Am J Dermatopathol 2010;32:541–9. [CrossRef]
- Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review. JDDG - Journal of the German Society of Dermatology 2020;18:826–33.
- Haniff S, Butler ME, Abou-Jaoude EA, Lenahan ML. An Unusual Trigger of Grover’s Disease (GD). Cureus 2023.
- Gantz M, Butler D, Goldberg M, Ryu J, McCalmont T, Shinkai K. Atypical features and systemic associations in extensive cases of Grover disease: A systematic review. J Am Acad Dermatol 2017;77:952-957.e1. [CrossRef]
- Davis MDP, Dinneen AM, Landa N, Gibson LE. Grover’s disease: clinicopathologic review of 72 cases. Mayo Clin Proc 1999;74:229–34. [CrossRef]
- Kotzerke M, Mitri F, Enk A, Toberer F, Haenssle H. A Case of Extensive Grover’s Disease in a Patient with a History of Multiple Non-Melanoma Skin Cancers. Case Rep Dermatol 2021;13:553–7.
- Aljarbou OZ, Asgari M, Al-Saidi N, Silloca-Cabana E, Alathamneh M, Sangueza O. Grover Disease With Epidermal Dysmaturation Pattern: a Common Histopathologic Finding. Am J Dermatopathol 2018; 0:1-5. [CrossRef]
- Fawcett HA, Miller JA. Persistent acantholytic dermatosis related to actinic damage. British Journal of Dermatology 1983; 109: 349-354. [CrossRef]
- Mokni M, Aractingi S, Grossman R, Verola O, Letessier S, Civatte J, Dubertret L. Persistent acantholytic dermatosis: sex-related differences in clinical presentation? Acta Derm Venereol. 1993;73(1):69-71. [CrossRef]
- Dobre A, Nedelcu R, Turcu G, Andrei R, Brinzea A, Balasescu E, Hulea I, Pantelimon F, Ion D. A rare case of Grover disease associated with multiple basal cell carcinomas. In Proceedings of European Academy of Dermatology & Venereology Congress, Amsterdam, Netherlands, in press 25-28 September 2024.
- Casanova JM, Pujol RM, Taberner R, Egido R, Fernandez E, Alomar A. Grover’s disease in patients with chronic renal failure receiving hemodialysis: clinicopathologic review of 4 cases. J Am Acad Dermatol 1999;41:1029–33. [CrossRef]
- Pinto-Pulido EL, Polo-Rodríguez I, González-Cañete M, Medina-Expósito I, Vélez-Velázquez MD, Medina-Montalvo S. Association of bullous pemphigoid and Grover disease induced by immune checkpoint therapy. An Bras Dermatol 2024;13:S0365-0596(24)00122-3. [CrossRef]
- Magdaleno-Tapial J, Valenzuela-Oñate C, Martínez-Doménech A, García-Legaz-Martínez M, Carballeira-Braña A, Sánchez-Carazo JL, Pérez-Ferriols A, Alegre-de Miquel V. Coexistence of Pemphigus Foliaceus and Grover Disease After a Radical Surgery for Basal Cell Carcinoma. Am J Dermatopathol 2019;41:744–746. [CrossRef]
- Aldana PC, Khachemoune A. Grover disease: review of subtypes with a focus on management options. Int J Dermatol 2020;59:543–50. [CrossRef]
- Errichetti E, De Francesco V, Pegolo E, Stinco G. Dermoscopy of Grover’s disease: Variability according to histological subtype. J Dermatol 2016;43:937–9. [CrossRef]
- Giacomel J, Zalaudek I, Argenziano G. Dermatoscopy of Grover’s disease and solitary acantholytic dyskeratoma shows a brown, star-like pattern. Australasian Journal of Dermatology 2012;53:315–6. [CrossRef]
- Specchio F, Argenziano G, Tiodorovic-Zivkovic D, et al. Dermoscopic clues to diagnose acantholytic dyskeratosis. Dermatol Pract Concept 2015;5:59. [CrossRef]
- Chalet M, Grover R, Ackerman AB. Transient Acantholytic Dermatosis: A Reevaluation. Arch Dermatol 1977;113:431–5. [CrossRef]
- Weaver J, Bergfeld WF. Grover disease (transient acantholytic dermatosis). Arch Pathol Lab Med 2009;133:1490–4. [CrossRef]
- Motaparthi K. Pseudoherpetic transient acantholytic dermatosis (Grover disease): case series and review of the literature. J Cutan Pathol 2017;44:486–9. [CrossRef]
- Grover RW. Transient Acantholytic Dermatosis: Electron Microscope Study. Arch Dermatol 1971;104:26–37. [CrossRef]
- Mota A, Correia TM, Lopes JM, Guimarães JM. Successful treatment of Grover’s disease with calcipotriol. European Journal of Dermatology 1998;8:33–5.
- Asahina A, Ishiko A, Saito I, Hasegawa K, Sawamura D, Nakano H. Grover’s Disease Following Multiple Bilateral Blaschko Lines: A Rare Clinical Presentation with Genetic and Electron Microscopic Analyses. Dermatology 2012;225:183–7. [CrossRef]
- Wang W, Amagai M, Ishiko A. Desmosome splitting is a primary ultrastructural change in the acantholysis of pemphigus. J Dermatol Sci 2009;54:59–61. [CrossRef]
- Hashimoto K, Moiin A, Chang MW, Tada J. Sudoriferous acrosyringeal acantholytic disease. J Cutan Pathol 1996;23:151–64. [CrossRef]
- Antley CM, Carrington PR, Mrak RE, Smoller BR. Grover’s disease (transient acantholytic dermatosis): relationship of acanthoiysis to acrosyringia. J Cutan Pathol 1998;25:545–9. [CrossRef]
- Bui CM, Vuong HG, Le MK, et al. Claudin-4 Upregulation in Acantholytic and Autoimmune-Mediated Bullous Disorders. Dermatopathology (Basel). 2023;11(1):1-7. Published 2023 Dec 21. [CrossRef]
- Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004 Jun;286(6):C1213-28. [CrossRef] [PubMed]
- Chiba H, Osanai M, Murata M, Kojima T, Sawada N. Transmembrane proteins of tight junctions. Biochim Biophys Acta. 2008 Mar;1778(3):588-600. [CrossRef] [PubMed]
- Kubo T, Sugimoto K, Kojima T, Sawada N, Sato N, Ichimiya S. Tight junction protein claudin-4 is modulated via ΔNp63 in human keratinocytes. Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):205-11. [CrossRef] [PubMed]
- Li J, Li Q, Geng S. All-trans retinoic acid alters the expression of the tight junction proteins Claudin-1 and -4 and epidermal barrier function-associated genes in the epidermis. Int J Mol Med. 2019 Apr;43(4):1789-1805. Erratum in: Int J Mol Med. 2024 Sep;54(3):75. doi: 10.3892/ijmm.2024.5399. PMID: 30816426; PMCID: PMC6414175. [CrossRef]
- Hashimoto K, Fujiwara K, Tada J, Harada M, Setoyama M, Eto H. Desmosomal dissolution in Grover’s disease, Hailey-Hailey’s disease and Darier’s disease. J Cutan Pathol 1995;22:488–501. [CrossRef]
- Phillips C, Kalantari-Dehaghi M, Marchenko S, et al. Is Grover’s disease an autoimmune dermatosis? Exp Dermatol 2013;22:781–4. [CrossRef]
- Roth-Carter QR, Burks HE, Ren Z, et al. Transcriptional profiling of rare acantholytic disorders suggests common mechanisms of pathogenesis. JCI Insight 2023;8. [CrossRef]
- Shelton E, Doolittle C, Shinohara MM, Thompson JA, Moshiri AS. Can't handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab. JAAD Case Rep. 2022;22:31-33. Published 2022 Feb 10. [CrossRef]
- Barei F, Torretta S, Morini N, Ferrucci S. A case of Grover disease treated with Dupilumab: Just serendipity or a future perspective? Dermatol Ther. 2022 May;35(5):e15429. [CrossRef] [PubMed] [PubMed Central]
- Butler DC, Kollhoff A, Berger T. Treatment of Grover disease with Dupilumab. JAMA Dermatol. 2021;153(3):353-356. [CrossRef]
- D'Ippolito D, Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018 Sep;43(9):532-535. [PubMed] [PubMed Central]
- Seli D, Ellis KT, Goldust M, Shah K, Hu R, Zhou J, McNiff JM, Choate KA. Association of Somatic ATP2A2 Damaging Variants With Grover Disease. JAMA Dermatol. 2023 Jul 1;159(7):745-749. [CrossRef] [PubMed] [PubMed Central]
- Hobbs RP, Amargo EV, Somasundaram A, et al. The calcium ATPase SERCA2 regulates desmoplakin dynamics and intercellular adhesive strength through modulation of PKCα signaling. FASEB J. 2011;25(3):990-1001. [CrossRef]

| Scheme . | Study type | Sample Size | Core Findings | Ref. |
|---|---|---|---|---|
| Davis et al. (1999) | Original article | 72 | 12 of GD patients (17%) associated skin cancer but details about skin cancer subtype were not available from this study | [6] |
| Aljarbou et al. (2018) | Original article | 33 | 20 cases (64%) of GD biopsies associated varying degrees of keratinocytic atypia that may represent a challenge to differentiate between GD with dysmaturative pattern and cutaneous keratinocyte cancers or pre-malignant tumors such as actinic keratosis (AKs), Bowen disease or basal cell carcinoma (BCC) | [8] |
| Kotzerke et al. (2021) | Case report | 1 | 69-year-old man misdiagnosed with multiple squamous cell carcinomas (SCCs), later identified as extensive GD after multiple biopsies and comprehensive analysis | [7] |
| Gantz et al. (2017) |
Systematic review | 72 | Extensive or atypical GD is associated with malignancy in 31 of cases (61%); half of non-hematologic cancers were metastatic melanoma (6 cases) | [5] |
| Fawcett HA & Miller JA (1983) |
Case series | 10 | 9 of 10 (90%) male patients associated at least one of the following: BCCs (6 patients), AKs (4 patients), SCCs including Bowen’s disease (2 patients), melanoma (1 patient) | [9] |
| Mokni M et al. (1993) |
Case report | 1 | 58 year-old man diagnosed with persistent acantholytic dermatosis associated with multiple AKs, SCCs, BCCs and Bowen’s disease | [10] |
| Dobre et al. (2024) | Case report | 1 | 62-year-old female with Darier-like pattern GD coexisted with 8 BCCs | [11] |
| Pinto-Pulido et al. (2023) | Case report | 1 | 90-year-old male developed GD and bullous pemphigoid after 2 months of PD-1 inhibitor treatment for invasive SCC | [13] |
| Magdaleno-Tapial et al. (2019) | Case report | 1 | Coexistence of GD with pemphigus foliaceus after invasive relapsing BCC treatment | [14] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).